Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF)
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.
MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.
MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.
Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.
iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.
In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.
The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.
MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.
The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.
Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.
Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.
Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.
Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.
Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.
Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.